IBM Watson and Guerbet Want to Tackle Prostate Cancer Diagnosis with AI

Guerbet has landed a second co-development agreement with IBM Watson Health. This time around, the two companies will develop an artificial intelligence tool to help clinicians detect, segment, characterize, and monitor prostate cancer. “The main diagnostic challenge with prostate cancer lies in identifying cancers requiring rapid treatment and those requiring only active surveillance while avoiding unnecessary biopsies," said David Gruen, MD, chief medical officer of imaging at IBM Watson Health. “For this reason, optimal patient outcomes depend on the rapid and accurate diagnosis and treatments that AI technologies can potentially help provide." Guerbet and IBM first joined forces in July 2018 to develop an AI program for diagnosing and monitoring patients with liver cancer. Based in the northeast suburbs of Paris, France, Guerbet specializes in contrast agents and solutions for diagnostic and interventional medical imaging. Francois Nicolas, the chief digital officer at Guerbet, said the companies will be leveraging progress made under the initial liver collaboration for the purposes of this second project in prostate cancer. “We are excited to further strengthen our partnership with Guerbet that has already been active in liver cancer”, said Anne Le Grand, General Manager, Imaging, Life Sciences and Oncology, IBM Watson Health. &a...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news